巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Deciphera Pharmaceuticals

    DCPH
    13.250
    0.090
    0.68%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Deciphera Pharmaceuticals - 延遲價格・最後更新於 01/07 12:14
    最高位
    13.410
    最低位
    12.760
    開市價
    --
    前收市價
    13.160
    成交量(千)
    56.57
    成交額(百萬)
    6.60
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    877.37
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    37.990 - 6.510
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Deciphera Pharmaceuticals
    證券代碼
    DCPH.US
    所屬板塊
    Drug Manufacturers - Specialty & Generic
    公司業務
    Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.
    發行量
    58552372
    公司總部
    200 Smith Street
    公司網址
    https://www.deciphera.com
    公司電郵
    jrobinson@deciphera.com
    公司電話
    +1 781 209-6400
    暫無內容

    關於

    Deciphera Pharmaceuticals(DCPH.US)所屬的行業板塊為Drug Manufacturers - Specialty & Generic。
    Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.
    詳細公司背景可參考: https://www.deciphera.com